Alternative Splicing and Cancer
198,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
  • Gebundenes Buch

This book "Alternative Splicing and Cancer" explores the crucial role alternative splicing, a post-transcriptional process, plays in human health and diseases, particularly cancer.

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book "Alternative Splicing and Cancer" explores the crucial role alternative splicing, a post-transcriptional process, plays in human health and diseases, particularly cancer.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Muzafar A. Macha, currently an Assistant Professor and Ramalingaswami Fellow at Watson-Crick Centre for Molecular Medicine, IUST, Kashmir, India, possesses a strong background in Biochemistry, Head and Neck Cancers (HNCs), and therapeutic modalities development. He previously served as a postdoctoral fellow and later as an Assistant Professor at the University of Nebraska Medical Centre (UNMC), leading an independent HNC research group. His notable contributions, recognized with multiple awards, include the identification of deregulated signaling pathways and innovative therapeutic strategies, published in esteemed journals. Ajaz A. Bhat, a staff scientist at Sidra Medicine, Qatar, has an extensive background in peptide-based vaccine development, deregulated signaling pathways, and drug targets for various cancers. After earning his Ph.D. from AIIMS, India, he undertook postdoctoral training at Vanderbilt University Medical School, USA, expanding his understanding of colorectal, gastric, and esophageal cancers. His high-impact research, published in prestigious journals, earned him recognition as an outstanding researcher, and he actively serves on several immunology and cancer societies' editorial and review boards. Surinder Kumar Batra, Chair of the Biochemistry and Molecular Biology Department at the University of Nebraska Medical Center (UNMC), USA, and Associate Director at Buffett Cancer Center, is renowned for his work on pancreatic cancer pathogenesis. His research focuses on mucins, glycoproteins with potential diagnostic and therapeutic applications. He has developed several genetically engineered models for cancer progression and received US patents on diagnostics and antibodies. With over 400 international peer-reviewed publications, he has trained 100+ scholars.